Monographs: Dosage forms: Specific monographs: Norethisterone tablets (Norethisteroni compressi)2016-01
Category. Progestational steroid. Storage. Norethisterone tablets should be kept in a well-closed container, protected from light. Additional information. Strength on the 6th invitation to manufacturers of reproductive health products to submit an expression of interest (EOI) for product evaluation to the WHO Prequalification Team - Medicines: 0.35 mg. Additional strengths available 0.625 and 5 mg. Requirements Comply with the monograph on Tablets. Definition. Norethisterone tablets contain not less than 90.0% and not more than 110.0% of the amount of Norethisterone (C20H26O2) stated on the label. Identity tests Either test A or test B may be applied.
Dissolution For 0.625 mg tablets. Carry out the test as described under 5.5 Dissolution test for solid oral dosage forms using as the dissolution medium 900 mL of a solution of 0.09% sodium lauril sulfate R in hydrochloric acid (~3.65 g/L) TS and rotating the paddle at 75 revolutions per minute. At 45 minutes withdraw a sample of 10 mL of the medium through an in-line filter and use the filtrate as solution (1). For solution (2) dissolve a suitable amount of norethisterone RS in 10 mL of ethanol (~750 g/L) TS and dilute to a suitable volume with dissolution medium to obtain a solution containing 0.7 µg per mL. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography using the chromatographic conditions as described under “Assay” but injecting alternately 50 µL each of the solutions (1) and (2). For each of the six tablets calculate the total amount of norethisterone (C20H26O2), in the medium, using the declared content of (C20H26O2) in norethisterone RS. The amount of norethisterone in solution for each tablet is not less than 80% (Q) of the amount declared on the label. For 0.35 mg tablets . Carry out the test as described above for 0.65 mg tablets but using 500 mL of a solution of 0.09% sodium laurilsulfate R in hydrochloric acid (~3.65 g/L) TS as the dissolution medium. Related substances Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography using a stainless steel column (15 cm x 4.6 mm) packed with end-capped particles of silica gel, the surface of which has been modified with chemically-bonded octylsilyl groups (5 µm). Use the following conditions for gradient elution: mobile phase A: water R; mobile phase B: acetonitrile R.
Operate with a flow rate of 1.0 mL per minute. As a detector use a variable wavelength spectrophotometer set at a wavelength of 254 nm and, for impurity C, D and I at 210 nm. Prepare the following solutions using as the diluent a mixture of 40 volumes of water R and 60 volumes of acetonitrile R. For solution (1) transfer a quantity of the powdered tablets, containing the equivalent of about 10 mg of norethisterone, in 10 mL and sonicate for 15 minutes. Stir vigorously for 15 minutes, centrifuge and use the supernatant. For solution (2) dilute a suitable volume of solution (1) to obtain a solution containing 1.0 µg of norethisterone per mL. For solution (3) dissolve 5.0 mg of norethisterone for system suitability RS (containing the impurities A, B, C, D, E, F, G and H) in the solvent and dilute to 2.0 mL. For solution (4) use a solution containing about 2.5 µg of ethinylestradiol RS (impurity I) per mL. Inject solution 20 µL of solution (3). The assay is not valid unless in the chromatogram recorded at the wavelength of 254 nm the peaks due to impurity B (with a relative retention of about 0.9) and due to norethisterone (retention time about 10 minutes) are baseline separated and the peak-to-valley ratio (Hp/Hv) is at least 1.2, where Hp is the height above the baseline of the peak due to impurity A (with a relative retention of about 0.8) and Hv is the height above the baseline of the lowest point of the curve separating this peak from the peak due to impurity B. Inject alternately 50 µL each of solution (1), (2) and (4). Use the chromatogram obtained with solution (3) and the chromatogram supplied with norethisterone for system suitability RS to identify the peaks due to the impurities A, B, C, D, E, F, G and H. The impurities are eluted at the following relative retention with reference to norethisterone (retention time about 10 minutes): impurity H about 0.3; impurity A about 0.8; impurity B about 0.9; impurity I about 1.1 (at 210 nm); impurity G about 1.5; impurity C about 1.6 (at 210 nm); impurity D about 1.7 (at 210 nm); impurity E about 2.3 and impurity F about 2.4. Use the chromatogram obtained with solution (4) to identify the peak due to impurity I. In the chromatogram obtained with solution (1):
Assay Either method A or B may be applied.
Uniformity of content The tablets comply with the test for 5.1 Uniformity of content for single-dose preparations using the following method of analysis. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography using the chromatographic conditions as described under “Assay”, method A. Prepare the following solutions using the mobile phase as diluent. For solution (1) transfer one tablet to a 25 mL volumetric flask. Add about 15 mL of the diluent, sonicate to disintegrate and shake for 10 minutes and dilute to volume. Centrifuge the suspension and use the clear supernatant liquid. For solution (2) use a solution containing 25 µg of norethisterone RS per mL (for 0.625 mg tablets ) or 14 µg of norethisterone RS per mL (for 0.35 mg tablets). Inject alternately 20 µL each of solution (1) and (2). Measure the areas of the peaks corresponding to norethisterone obtained in the chromatograms and calculate the content of norethisterone (C20H26O2) in each tablet, using the declared content of C20H 26O2 in norethisterone RS. Impurities The impurities limited by the requirements of this monograph include those listed in the monograph on Norethisterone. |